Multidrug Resistance in Ovarian Cancer: Comparing an Immunocytochemical Study and ATP-Tumor Chemosensitivity Assay

Abstract The aim of our study was to evaluate the possible prognostic and predictive significance of the expression of P-glycoprotein, a transmembrane transport protein related to multidrug resistance, in previously untreated patients with FIGO stage III ovarian cancer; to compare the results of immunocytochemical analysis of tissue sections of tumors to the in vitro chemosensitivity to cytotoxic drug of fresh samples of the same tumors; and to evaluate survival in women who underwent the same surgical treatment and the same adjuvant chemotherapy.

[1]  I. Cree,et al.  Correlation of drug response with the ATP tumorchemosensitivity assay in primary FIGO stage III ovarian cancer. , 2000, Gynecologic oncology.

[2]  J. Nesland,et al.  P-glycoprotein expression is a marker for chemotherapy resistance and prognosis in advanced ovarian cancer. , 2000, Anticancer research.

[3]  I. Cree,et al.  Chemosensitivity testing of human tumors using a microplate adenosine triphosphate luminescence assay: clinical correlation for cisplatin resistance of ovarian carcinoma. , 1995, Cancer research.

[4]  I. Cree,et al.  Methotrexate chemosensitivity by ATP luminescence in human leukemia cell lines and in breast cancer primary cultures: comparison of the TCA-100 assay with a clonogenic assay. , 1995, Anti-cancer drugs.

[5]  H. Lenz,et al.  Quantitative analysis of folylpolyglutamate synthetase gene expression in tumor tissues by the polymerase chain reaction: marked variation of expression among leukemia patients. , 1994, Oncology research.

[6]  I. Cree,et al.  TCA-100 tumour chemosensitivity assay: differences in sensitivity between cultured tumour cell lines and clinical studies. , 1994, Journal of bioluminescence and chemiluminescence.

[7]  P. Andreotti,et al.  In vitro activity of titanocenedichloride in human renal cell carcinoma compared to conventional antineoplastic agents. , 1994, Anticancer research.

[8]  I. Cree,et al.  Heterogeneity of chemosensitivity in human breast carcinoma: use of an adenosine triphosphate (ATP) chemiluminescence assay. , 1993, European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology.

[9]  B. Sevin,et al.  Chemosensitivity testing in ovarian cancer , 1993, Cancer.

[10]  D. Scudiero,et al.  Feasibility of a high-flux anticancer drug screen using a diverse panel of cultured human tumor cell lines. , 1991, Journal of the National Cancer Institute.

[11]  M. Melamed,et al.  Expression of the multidrug resistance gene product (P-glycoprotein) in human normal and tumor tissues. , 1990, The journal of histochemistry and cytochemistry : official journal of the Histochemistry Society.

[12]  A. Fojo,et al.  Multidrug resistance in ovarian cancer , 1987, Cancer.

[13]  W. T. Beck,et al.  The cell biology of multiple drug resistance. , 1987, Biochemical pharmacology.

[14]  I. Pastan,et al.  Multiple-drug resistance in human cancer. , 1987, The New England journal of medicine.

[15]  Y. Maehara,et al.  The ATP assay is more sensitive than the succinate dehydrogenase inhibition test for predicting cell viability. , 1987, European journal of cancer & clinical oncology.

[16]  S. Rodenhuis,et al.  Development of an assay system for the detection and classification of methotrexate resistance in fresh human leukemic cells. , 1986, Cancer research.

[17]  J. Riordan,et al.  Amplification of P-glycoprotein genes in multidrug-resistant mammalian cell lines , 1985, Nature.

[18]  V. Ling,et al.  Detection of P-glycoprotein in ovarian cancer: a molecular marker associated with multidrug resistance. , 1985, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[19]  J. Riordan,et al.  Daunorubicin-resistant Chinese hamster ovary cells expressing multidrug resistance and a cell-surface P-glycoprotein. , 1983, Cancer research.

[20]  D. Alberts,et al.  Quantitation of differential sensitivity of human-tumor stem cells to anticancer drugs. , 1978, The New England journal of medicine.

[21]  R. Fisher,et al.  Chemotherapy of ovarian cancer. , 1978, The Surgical clinics of North America.

[22]  G. Mickisch.  Multidrug Resistance , 1996, Der Urologe A.

[23]  I. Cree,et al.  Comparison of MTT and ATP-based assays for the measurement of viable cell number. , 1995, Journal of bioluminescence and chemiluminescence.

[24]  K. Danenberg,et al.  Quantitation of thymidylate synthase, dihydrofolate reductase, and DT-diaphorase gene expression in human tumors using the polymerase chain reaction. , 1992, Cancer research.

[25]  V. Ling,et al.  Detection of P-glycoprotein in multidrug-resistant cell lines by monoclonal antibodies , 1985, Nature.

[26]  L. Kangas,et al.  Bioluminescence of cellular ATP: a new method for evaluating cytotoxic agents in vitro. , 1984, Medical biology.

[27]  D. V. Von Hoff,et al.  In vitro methods to predict for patient response to chemotherapy. , 1980, Advances in pharmacology and chemotherapy.

[28]  A. Hamburger,et al.  Primary bioassay of human tumor stem cells. , 1977, Science.

[29]  C A SALVATORE,et al.  [Carcinoma of the ovary]. , 1960, Anais brasileiros de ginecologia.